The HemOnc Pulse
Blood Cancers Today brings you The HemOnc Pulse, a podcast covering all topics in the world of hematologic oncology.
Advertisement
Advertisement
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
"MRD positivity is an indication to go to transplant in these patients,” Dr. Radich said.
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
The debate on the future of Bruton's tyrosine kinase (BTK) inhibitors in CLL.
Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.
We saw patients [who] were going to die, and it saved their life and then it's gone and it's shocking," she explained.
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Dr. Fonseca offers his thoughts on the future of multiple myeloma treatment and more.
Jonathan Friedberg, MD, MMSc, discusses the trial and its implications for the field.
Updates From Other BCT Partners
Dr. Rakesh Popat joins the hosts of “Blood Cancer Talks” to highlight myeloma research presented at ASH 2024.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
The group discussed four abstracts on belantamab mafodotin in MM presented at EHA 2024 and ASCO 2024.
Andrew Evens, DO, MSc, FACP, discusses tailoring management by patient fitness in this setting plus recent clinical trials.
On this episode, Andrew Wei, MBBS, PhD, goes especially in depth regarding venetoclax plus azacitidine combination.
“Blood Cancer Talks" hosts are joined by Timothy Schmidt, MD, to discuss quadruplet therapy for myeloma.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.